English | Español

Drug Channels Institute
+ Pharmaceuticals
Patient Daily | Feb 3, 2026

Drug Channels President on 340B: 'no one knows where the 340B profits go, or which patients benefit'
+ Regulatory
Patient Daily | Oct 16, 2025

USC Schaeffer Center Senior Fellow: 340B spread pricing 'makes healthcare more expensive'
+ Pharmaceuticals
Patient Daily | Apr 15, 2025

President of Drug Channels Institute: 'Hospital prices are significantly higher at large 340B hospitals'

Trending
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Regulatory
M. R. Armstrong | Aug 4, 2026

Public Policy Solutions on 340B: 'The program has enriched big hospital execs'
+ Pharmaceuticals
Patient Daily | Aug 5, 2026

Bristol Myers Squibb and AstraZeneca reportedly in merger talks amid industry changes